 Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 4 | 6 | | 1996 | 2 | 2 | 4 | | 1997 | 4 | 0 | 4 | | 1998 | 3 | 2 | 5 | | 1999 | 2 | 1 | 3 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 0 | 7 | 7 | | 2003 | 1 | 4 | 5 | | 2004 | 4 | 3 | 7 | | 2005 | 2 | 8 | 10 | | 2006 | 8 | 4 | 12 | | 2007 | 7 | 3 | 10 | | 2008 | 4 | 7 | 11 | | 2009 | 4 | 6 | 10 | | 2010 | 12 | 4 | 16 | | 2011 | 11 | 5 | 16 | | 2012 | 13 | 7 | 20 | | 2013 | 12 | 6 | 18 | | 2014 | 6 | 10 | 16 | | 2015 | 11 | 8 | 19 | | 2016 | 11 | 10 | 21 | | 2017 | 15 | 10 | 25 | | 2018 | 7 | 1 | 8 | | 2019 | 7 | 7 | 14 | | 2020 | 10 | 3 | 13 | | 2021 | 6 | 7 | 13 | | 2022 | 6 | 9 | 15 | | 2023 | 4 | 4 | 8 | | 2024 | 7 | 2 | 9 | | 2025 | 7 | 2 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Chakraborty A, Giraldo-Arias J, Merl-Pham J, Dick E, Mastalerz M, Zöller M, Marchi H, Le Gleut R, Hatz RA, Behr J, Hilgendorff A, Hauck SM, Staab-Weijnitz CA. Cholesterol Regulates Airway Epithelial Cell Differentiation by Inhibiting p53 Nuclear Translocation. Int J Mol Sci. 2025 Aug 27; 26(17).
-
Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Sojitra P, Wiredja D, Zhou Q, Chang H, Patil E, Patel JL, Patel AB, Menon M, Ghosh S, Wool GD, Arber DA, Pan Z, Findley A, Badar T, Tariq H, Sallman D, Bell RC, Perry A, Haferlach C, Fitzpatrick C, Venkataraman G. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
-
McGivney GR, Brockman QR, Borcherding N, Scherer A, Rauckhorst AJ, Gutierrez WR, Solst SR, Heer CD, Warrier A, Floyd W, Kirsch DG, Knepper-Adrian VL, Laverty EA, Roughton GA, Spitz DR, Taylor EB, Dodd RD. Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs. Sci Adv. 2025 Aug 15; 11(33):eadu2906.
-
Nguyen KA, McLemore LE, Ke Y, DePledge LN, Smith LP, Bian L, Aleman JD, Debretsion D, Wong E, Manning N, Wang XJ, Young CD. Activation of PI3K and deletion of p53 in keratin 15-expressing mouse mammary cells induces tumor heterogeneity and plasticity modeling metaplastic breast cancer. J Pathol. 2025 Oct; 267(2):213-224.
-
Chattopadhyay M, Jenkins EC, Janssen W, Mashaka T, Germain D. Differential ER stress responses during lactation and postpartum outcomes in mice depending on their mitochondrial genotype. Nat Commun. 2025 Jul 11; 16(1):6432.
-
Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia. 2025 Sep; 39(9):2087-2098.
-
Cotton K, Comer C, Caporali S, Butera A, Gurres S, Capradossi F, D'Alessandro A, Amelio I, Niklison-Chirou MV. Lipidome atlas of p53 mutant variants in pancreatic cancer. Biol Direct. 2025 Apr 11; 20(1):51.
-
Andrysik Z, Espinosa JM. Harnessing p53 for targeted cancer therapy: new advances and future directions. Transcription. 2025 Feb; 16(1):3-46.
-
Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 Feb; 193:119-129.
-
Nakajima R, Zhou Y, Shirasawa M, Nishimura N, Zhao L, Fikriyanti M, Kamiya Y, Iwanaga R, Bradford AP, Shinmyozu K, Nishibuchi G, Nakayama JI, Kurayoshi K, Araki K, Ohtani K. DEAD/H Box 5 (DDX5) Augments E2F1-Induced Cell Death Independent of the Tumor Suppressor p53. Int J Mol Sci. 2024 Dec 10; 25(24).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|